Loading viewer...
investor_presentation
Format: PDF investor_presentation
Crinetics Pharmaceuticals is developing GPCR-targeted oral small molecules for endocrine disorders and endocrine-related tumors, with lead candidate paltusotine in Phase 3 trials for acromegaly. The company combines a proprietary GPCR drug discovery platform with global endocrinology clinical capabilities and aims to become a fully-integrated endocrine company with multiple late-stage programs.
presentation
ACG Electric Metals: Green Metals Supplier Platform 2023
investor_presentationinvestor_presentation
59 Pages
ACG Acquisition Company Limited